Skip to content

Pilot Phase for an Acute Evaluation of a Non-Implantable Electrical Continence Device

Pilot Phase for an Acute Evaluation of a Non-Implantable Electrical Continence Device

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04001426
Enrollment
2
Registered
2019-06-28
Start date
2019-04-04
Completion date
2019-12-31
Last updated
2021-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Bladder, Overactive

Keywords

Overactive Bladder, Women, Neuromodulation, Bioelectronic Medicine

Brief summary

The purpose of this feasibility clinical investigation is to investigate a new medical device treatment for Overactive Bladder (OAB) in women.

Detailed description

The FemPulse System is a vaginal ring intended to provide mild electrical stimulation to nerves that regulate bladder function. It is believed that stimulation of these nerves may help relieve the symptoms of OAB.

Interventions

DEVICEThe FemPulse System

Non-invasive monitoring during activation of the FemPulse System

Sponsors

FemPulse Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Intervention model description

Subjects will wear a device and will be monitored non-invasively during activation of the device.

Eligibility

Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Normal healthy women ≥ 21 years old * Using contraception if of reproductive age

Exclusion criteria

* Pregnant, recently pregnant or actively trying to conceive * Prior hysterectomy * Current or recent urinary tract or vaginal infection

Design outcomes

Primary

MeasureTime frameDescription
Autonomic nervous system responseUp to 6 hoursThe Quantitative Sudomotor Axon Reflex Test (QSART) will be used to detect changes in autonomic nervous system activity during device activation
Evoked Potential responseUp to 6 hoursSurface electrodes will be used to detect whether evoked potentials are generated during device activation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026